Related Experiment Video
Updated: Feb 15, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Clinical trials in patients with heart failure and preserved left ventricular ejection fraction
John G F Cleland1, Pierpaolo Pellicori2, Riet Dierckx2
1National Heart & Lung Institute, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield Hospitals NHS Trust, Imperial College, London, UK.
Abstract:
There is no robust evidence that any treatment can modify the natural history of patients with heart failure and preserved left ventricular ejection fraction (HFpEF), although most agree that diuretics can control congestion and improve symptoms. HFpEF is often complicated by systemic and pulmonary hypertension, atrial fibrillation, obesity, chronic lung and kidney disease, lack of physical fitness, and old age that can complicate both diagnosis and management. Further trials should phenotype patients precisely and create better definitions of HFpEF based on biomarkers.
Related Concept Videos
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Pathophysiology of Heart Failure

